Base de dados : MEDLINE
Pesquisa : D03.383.129.539.850.077.150 [Categoria DeCS]
Referências encontradas : 1325 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 133 ir para página                         

  1 / 1325 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29289696
[Au] Autor:Passoni MT; Kristensen MN; Morais RN; Woitkowiak C; Boareto AC; da Silva Amaral BA; Grechi N; Dalsenter PR; Munkboel CH; Styrishave B; Kristensen DM; Gomes C; van Ravenzwaay B; Martino-Andrade AJ
[Ad] Endereço:Department of Pharmacology, Reproductive Toxicology Laboratory, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.
[Ti] Título:Assessment of the analgesic dipyrone as a possible (anti)androgenic endocrine disruptor.
[So] Source:Toxicol Lett;285:139-147, 2018 Mar 15.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Mild analgesics have been associated with antiandrogenic effects, but there are no such studies on dipyrone, despite its high prevalence of use in many countries. We examined the production of steroid hormones in human H295R cells after exposure to dipyrone and two metabolites, 4-Methylaminoantipyrine (MAA) and 4-Aminoantipyrine (AA), as well as fetal testicular testosterone production in rats following maternal dipyrone exposure. Androgen agonistic/antagonistic effects were examined in vitro for dipyrone and its metabolites in the Yeast Androgen Screen (YAS) assay and in vivo for dipyrone through the Hershberger assay. In vitro we tested dipyrone, MAA, and AA (0.1-1000 µM) while in vivo we used dipyrone (50, 100, 200 mg/kg/day). In the H295R assay, dipyrone, MAA and AA reduced the production of androgens and corticosteroids. Testosterone was reduced at concentrations 4-13 times higher than the maximum plasma concentrations reported in humans for MAA and AA. No effects were observed in the fetal testosterone production assay. In the YAS and Hershberger assays, no androgen agonistic/antagonistic activities were observed. These results indicate that dipyrone and its metabolites do not interact with the androgen receptor, but have the potential to inhibit steroidogenesis, however only at concentrations that are not relevant under normal medical use.
[Mh] Termos MeSH primário: Analgésicos/toxicidade
Antagonistas de Receptores de Andrógenos/toxicidade
Androgênios/toxicidade
Dipirona/toxicidade
Disruptores Endócrinos/toxicidade
[Mh] Termos MeSH secundário: Analgésicos/sangue
Antagonistas de Receptores de Andrógenos/sangue
Androgênios/sangue
Animais
Bioensaio
Linhagem Celular Tumoral
Dipirona/sangue
Disruptores Endócrinos/sangue
Feminino
Seres Humanos
Masculino
Gravidez
Efeitos Tardios da Exposição Pré-Natal/sangue
Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente
Ratos
Ratos Wistar
Receptores Androgênicos/genética
Receptores Androgênicos/metabolismo
Testículo/efeitos dos fármacos
Testículo/embriologia
Testículo/metabolismo
Testosterona/biossíntese
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Androgen Receptor Antagonists); 0 (Androgens); 0 (Endocrine Disruptors); 0 (Receptors, Androgen); 3XMK78S47O (Testosterone); 6429L0L52Y (Dipyrone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180101
[St] Status:MEDLINE


  2 / 1325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374698
[Au] Autor:Bundscherer AC; Malsy M; Gruber MA; Graf BM; Sinner B
[Ad] Endereço:Department of Anesthesiology, University of Regensburg, Regensburg, Germany anika.bundscherer@ukr.de.
[Ti] Título:Acetaminophen and Metamizole Induce Apoptosis in HT 29 and SW 480 Colon Carcinoma Cell Lines .
[So] Source:Anticancer Res;38(2):745-751, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: The perioperative phase is supposed to be a period with high vulnerability for cancer dissemination. Acetaminophen and metamizole are common analgesics administered during this phase. We investigated the effect of acetaminophen, metamizole and 4-methylaminoantipyrine (MAA) on proliferation and apoptosis of colon carcinoma cell lines (SW 480 and HT 29). MATERIALS AND METHODS: Proliferation was detected by cell proliferation ELISA BrdU, and apoptosis by Annexin V staining. Cytochrome c and caspase 3, 8 and 9 expression levels were detected by western blot. RESULTS: Acetaminophen, metamizole or MAA caused slight changes in proliferation. Acetaminophen, metamizole or the combination increased apoptosis in both cell lines. All agents decreased caspase 3 and 8 expression in SW480. Acetaminophen decreased caspase 9 expression in both cell lines. CONCLUSION: In clinically relevant doses, acetaminophen and/or metamizole induce apoptosis in both colon cancer cell lines. Both mitochondrial and death receptor pathways might be involved in acetaminophen-induced apoptosis.
[Mh] Termos MeSH primário: Acetaminofen/farmacologia
Analgésicos não Entorpecentes/farmacologia
Apoptose/efeitos dos fármacos
Neoplasias do Colo/tratamento farmacológico
Dipirona/farmacologia
[Mh] Termos MeSH secundário: Aminopirina/análogos & derivados
Aminopirina/farmacologia
Anti-Inflamatórios não Esteroides/farmacologia
Western Blotting
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Neoplasias do Colo/patologia
Células HT29
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Non-Narcotic); 0 (Anti-Inflammatory Agents, Non-Steroidal); 01704YP3MO (Aminopyrine); 362O9ITL9D (Acetaminophen); 6429L0L52Y (Dipyrone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  3 / 1325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28763499
[Au] Autor:Andrade PHS; Lobo IMF; da Silva WB
[Ad] Endereço:Universidade Federal de Sergipe, São Cristóvão, Sergipe, Brazil.
[Ti] Título:Risk factors for adverse drug reactions in pediatric inpatients: A cohort study.
[So] Source:PLoS One;12(8):e0182327, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The present study aims to identify the risk factors for adverse drug reactions (ADR) in pediatric inpatients. METHODS: A prospective cohort study in one general pediatric ward in a hospital in Northeast Brazil was conducted in two stages: the first stage was conducted between August 17th and November 6th, 2015, and the second one between March 1st and August 25th, 2016. We included children aged 0-14 years 11 months hospitalized with a minimum stay of 48 hours. Observed outcomes were the ADR occurrence and the time until the first ADR observed. In the univariate analysis, the time to the first ADR was compared among groups using a log-rank test. For the multivariate analysis, the Cox regression model was used. RESULTS: A total of 173 children (208 admissions) and 66 ADR classified as "definite" and "probable" were identified. The incidence rate was 3/100 patient days. The gastro-intestinal system disorders were the main ADR observed (28.8%). In addition, 22.7% of the ADR were related to antibacterials for systemic use and 15.2% to general anesthesia. Prior history of ADR of the child [hazard ratio (HR) 2.44; 95% confidence interval (CI) 1.19-5.00], the use of meglumine antimonate (HR 4.98; 95% CI 1.21-20.54), antibacterial for systemic use (HR 2.75; 95% CI 1.08-6.98) and antiepileptic drugs (HR 3.84; 95% CI 1.40-10.56) were identified risk factors for ADR. CONCLUSIONS: We identified as risk factors the prior history of ADR of the child and the use of meglumine antimonate, antibacterial for systemic use and antiepileptic drugs.
[Mh] Termos MeSH primário: Antibacterianos/efeitos adversos
Anticonvulsivantes/efeitos adversos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Meglumina/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Sistemas de Notificação de Reações Adversas a Medicamentos
Anestesia Geral
Brasil
Criança
Pré-Escolar
Clonazepam/efeitos adversos
Estudos de Coortes
Fibrose Cística/tratamento farmacológico
Dipirona/efeitos adversos
Feminino
Gastroenteropatias/complicações
Gastroenteropatias/tratamento farmacológico
Hospitalização
Hospitais Pediátricos
Seres Humanos
Lactente
Recém-Nascido
Pacientes Internados
Masculino
Omeprazol/efeitos adversos
Pediatria
Projetos Piloto
Modelos de Riscos Proporcionais
Análise de Regressão
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anticonvulsants); 5PE9FDE8GB (Clonazepam); 6429L0L52Y (Dipyrone); 6HG8UB2MUY (Meglumine); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182327


  4 / 1325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28574391
[Au] Autor:Gorgiladze T; Nozadze I; Abzianidze E; Tsagareli M
[Ad] Endereço:1Tbilisi State Medical University; 2Beritashvili Center for Experimental Biomedicine, Tbilisi Georgia.
[Ti] Título:NON-STEROIDAL ANTI-INFLAMMATORY DRUGS'S ANTINOCICEPTION MEDIATED BY THE OPIOID MECHANISM IN THE NUCLEUS RAPHE MAGNUS.
[So] Source:Georgian Med News;(265):99-104, 2017 Apr.
[Is] ISSN:1512-0112
[Cp] País de publicação:Georgia (Republic)
[La] Idioma:eng
[Ab] Resumo:It has been established that the midbrain periaqueductal gray matter (PAG) and rostral ventro-medial medulla (RVM) are involved in the descending pain control system. The latter involves the midline nucleus raphe magnus (NRM) and adjacent reticular formation. These brain structures are is one of important parts of CNS circuit that controls nociceptive transmission at the level of spinal cord. Here we report that microinjection of commonly used non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac, ketorolac, metamizol, and xefocam into the NRM produces strong antinociception which is mediated by the opioid mechanism. The experiments were carried out on experimental and control (saline) white albino male rats. Animals were implanted with a guide cannula in the NRM and tested for antinociception following microinjection of NSAIDs into the NRM in the tail flick (TF) and hot plate (HP) tests. The analysis of variance (ANOVA) with post-hoc Tukey-Kramer multiple comparison tests were used for statistical evaluation. The obtained data show that microinjection of these NSAIDs into the NRM produced antinociception as revealed by a latency increase in the tail-flick (TF) and hot plate (HP) latencies compared to the saline control microinjected into the same nucleus. Furthermore, we definitely showed that pre-treatment with opioid antagonist naloxone in the NRM diminishes NSAID-induced antinociception expressing in significant decrease in TF and HP latencies (P<0.001). The present findings support the concept that antinociceptive effects of NSAIDs are mediated via an endogenous opioid system possibly involving the descending pain modulatory circuit.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/farmacologia
Naloxona/farmacologia
Antagonistas de Entorpecentes/farmacologia
Nociceptividade/efeitos dos fármacos
Núcleo Magno da Rafe/efeitos dos fármacos
Peptídeos Opioides/metabolismo
[Mh] Termos MeSH secundário: Animais
Diclofenaco/farmacologia
Dipirona/farmacologia
Cetorolaco/farmacologia
Masculino
Microinjeções
Núcleo Magno da Rafe/fisiologia
Piroxicam/análogos & derivados
Piroxicam/farmacologia
Ratos
Tempo de Reação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Narcotic Antagonists); 0 (Opioid Peptides); 13T4O6VMAM (Piroxicam); 144O8QL0L1 (Diclofenac); 36B82AMQ7N (Naloxone); 6429L0L52Y (Dipyrone); ER09126G7A (lornoxicam); YZI5105V0L (Ketorolac)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170603
[St] Status:MEDLINE


  5 / 1325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28294366
[Au] Autor:Guzmán-Priego CG; Méndez-Mena R; Baños-González MA; Araiza-Saldaña CI; Castañeda-Corral G; Torres-López JE
[Ad] Endereço:Laboratorio Mecanismos del Dolor, Centro de Investigación, División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco, Villahermosa, Tabasco, México.
[Ti] Título:Antihyperalgesic Effects of Indomethacin, Ketorolac, and Metamizole in Rats: Effects of Metformin.
[So] Source:Drug Dev Res;78(2):98-104, 2017 Mar.
[Is] ISSN:1098-2299
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Preclinical Research Metformin-dependent mechanisms have been implicated in the antinociceptive effect of some non-steroidal anti-inflammatory drugs (NSAIDs). In this study, the effect of local peripheral or systemic administration of metformin on the local peripheral or systemic antinociception induced by indomethacin, ketorolac and metamizole was assessed in the rat carrageenan-induced thermal hyperalgesia model. Rats were injected with carrageenan (1%, 50 µl) into the right hindpaw which reduced paw withdrawal latency, a measure of thermal hyperalgesia. Local peripheral or systemic administration of indomethacin, ketorolac or metamizole dose-dependently reduced carrageenan-induced thermal hyperalgesia. Local peripheral pre-treatment with metformin (800 µg/paw) partially inhibited the anti-hyperalgesic effect of indomethacin (200 µg/paw) and metamizole (200 µg/paw), but not that of ketorolac (200 µg/paw). In contrast, systemic pre-treatment with metformin (200 mg/kg) attenuated the antihyperalgesic effect of metamizole (10 mg/kg), but not that observed with either indomethacin (10 mg/kg) or ketorolac (10 mg/kg). These findings suggest that some but not all NSAIDs have effects mediated by metformin-dependent mechanisms. Drug Dev Res 78 : 98-104, 2017. ©2017 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/administração & dosagem
Carragenina/efeitos adversos
Hiperalgesia/tratamento farmacológico
Metformina/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios não Esteroides/uso terapêutico
Dipirona/administração & dosagem
Dipirona/uso terapêutico
Relação Dose-Resposta a Droga
Interações Medicamentosas
Temperatura Alta
Hiperalgesia/induzido quimicamente
Indometacina/administração & dosagem
Indometacina/uso terapêutico
Cetorolaco/administração & dosagem
Cetorolaco/uso terapêutico
Masculino
Metformina/uso terapêutico
Ratos
Ratos Sprague-Dawley
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 6429L0L52Y (Dipyrone); 9000-07-1 (Carrageenan); 9100L32L2N (Metformin); XXE1CET956 (Indomethacin); YZI5105V0L (Ketorolac)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1002/ddr.21379


  6 / 1325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28276328
[Au] Autor:Vuik FE; Koehestanie P; Herbers AH; Terhaar Sive Droste JS
[Ad] Endereço:Department of Gastroenetrology, Jeroen Bosch Hospital, Den Bosch, the Netherlands.
[Ti] Título:Chronic use of metamizole: not so safe after all?
[So] Source:Neth J Med;75(2):81-83, 2017 Mar.
[Is] ISSN:1872-9061
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Metamizole can be used in both short- and long-term pain relief therapies and has a relatively favourable safety profile compared with classic NSAIDs. Metamizole is also infamous because of its potential fatal adverse drug reaction, agranulocytosis. Although this risk varies, it is estimated to occur in less than one million metamizole prescriptions. We describe a case of a 68-year-old patient who developed leukopenia after using metamizole.
[Mh] Termos MeSH primário: Agranulocitose/induzido quimicamente
Anti-Inflamatórios não Esteroides/efeitos adversos
Dipirona/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Seres Humanos
Masculino
Fatores de Tempo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 6429L0L52Y (Dipyrone)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE


  7 / 1325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28219765
[Au] Autor:Veronesi VB; Batista TH; Ribeiro AC; Giusti-Paiva A; Vilela FC
[Ad] Endereço:Departamento de Ciências Fisiológicas, Instituto de Ciências Biomédicas, Universidade Federal de Alfenas (Unifal-MG), Alfenas, Minas Gerais, Brazil; Programa de Pós-Graduação em Biociências Aplicadas à Saúde, Brazil.
[Ti] Título:Maternal dipyrone treatment during lactation in mice reduces maternal behavior and increases anxiety-like behavior in offspring.
[So] Source:Int J Dev Neurosci;58:74-81, 2017 May.
[Is] ISSN:1873-474X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Dipyrone (metamizole), a powerful drug, is widely used as an analgesic and antipyretic; however, the safety of its use during lactation and the potential impact on the offspring are not well established. This study aimed to determine the effect of maternal dipyrone treatment during lactation on offspring development and emotional behavior and on the dam's maternal behavior. Hence, on postnatal day (PND) 2, drinking water only or drinking water containing dipyrone at doses of 100, 300, and 500mg/kg/day, were offered to lactating mothers up to PND9. Thereafter, all mice were provided regular drinking water. On PND2, all litters were culled to 8 pups (4 males and 4 females). Maternal behavior was evaluated at PND3, 6, 9, and 12, and at PND7 we evaluated locomotor activity in the open field. Reflex parameters and physical development of offspring were evaluated during lactation. At PND7, analysis of ultrasonic vocalization (USV) was performed. When the animals reached adolescence, we evaluated their performance in the open field, elevated plus maze (EPM), and marble burying. Our data demonstrated that maternal dipyrone treatment during lactation not only altered maternal behavior and the onset of physical and neurodevelopmental landmarks but also had an impact on anxiety-like behavior in offspring.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/toxicidade
Ansiedade/induzido quimicamente
Dipirona/toxicidade
Comportamento Materno/efeitos dos fármacos
Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente
Efeitos Tardios da Exposição Pré-Natal/fisiopatologia
[Mh] Termos MeSH secundário: Fatores Etários
Animais
Animais Recém-Nascidos
Deficiências do Desenvolvimento/etiologia
Relação Dose-Resposta a Droga
Comportamento de Ingestão de Líquido/efeitos dos fármacos
Comportamento Exploratório/efeitos dos fármacos
Feminino
Seres Humanos
Lactação/efeitos dos fármacos
Masculino
Aprendizagem em Labirinto/efeitos dos fármacos
Camundongos
Gravidez
Vocalização Animal/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 6429L0L52Y (Dipyrone)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170330
[Lr] Data última revisão:
170330
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE


  8 / 1325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28144710
[Au] Autor:Hoenicka M; Gorki H; Traeger K; Liebold A
[Ad] Endereço:Department of Cardiothoracic and Vascular Surgery, University of Ulm Medical Center, Albert-Einstein-Allee 23, 89081, Ulm, Germany. markus.hoenicka@uniklinik-ulm.de.
[Ti] Título:Selective venous vasodilator properties of the analgesic metamizole (dipyrone) in a human ex vivo model-implications for postoperative pain management.
[So] Source:Naunyn Schmiedebergs Arch Pharmacol;390(5):519-526, 2017 May.
[Is] ISSN:1432-1912
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Metamizole (dipyrone) is a first-line, non-opioid analgesic used for postoperative pain management. Clinical data and animal experiments indicate a possible vasodilator action of this drug. We investigated the effects of metamizole on human artery and vein tone in an ex vivo model to assess potential contributions to venous pooling. Excess segments of bypass grafts were harvested during coronary artery bypass grafting procedures. Tensions were measured in an organ bath for 120 min after adding metamizole to the preconstricted vessels. Contribution of endothelium was assessed in endothelium-denuded vessels, and indometacin was used to identify cyclooxygenase-mediated effects. Internal mammary arteries (n = 6) constricted after addition of 1, 3, and 10 µM metamizole and remained constricted at the lower doses. Transient constrictions also occurred in saphenous veins (n = 20), but veins relaxed below solvent controls after 20 min at all concentrations. Endothelium removal (n = 12) and cyclooxygenase inhibition (n = 12) suppressed the vasoconstrictor effect but not the vasodilator effect. Metamizole and its metabolites display counteracting effects on blood vessel tone ex vivo. The vasoconstrictor effect is mediated by cyclooxygenase-derived products. The net effect is site-specific, resulting in a selective venous vasodilator action. This may exacerbate unwanted venous pooling during postoperative pain therapy.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/farmacologia
Dipirona/farmacologia
Artéria Torácica Interna/efeitos dos fármacos
Dor Pós-Operatória/tratamento farmacológico
Veia Safena/efeitos dos fármacos
Vasoconstrição/efeitos dos fármacos
Vasoconstritores/farmacologia
Vasodilatação/efeitos dos fármacos
Vasodilatadores/farmacologia
[Mh] Termos MeSH secundário: Idoso
Anti-Inflamatórios não Esteroides/toxicidade
Inibidores de Ciclo-Oxigenase/farmacologia
Dipirona/toxicidade
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Técnicas In Vitro
Indometacina/farmacologia
Masculino
Meia-Idade
Dor Pós-Operatória/fisiopatologia
Fatores de Tempo
Vasoconstritores/toxicidade
Vasodilatadores/toxicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Cyclooxygenase Inhibitors); 0 (Vasoconstrictor Agents); 0 (Vasodilator Agents); 6429L0L52Y (Dipyrone); XXE1CET956 (Indomethacin)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170202
[St] Status:MEDLINE
[do] DOI:10.1007/s00210-017-1347-6


  9 / 1325 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28084009
[Au] Autor:Derry S; Wiffen PJ; Moore RA
[Ad] Endereço:Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), University of Oxford, Pain Research Unit, Churchill Hospital, Oxford, Oxfordshire, UK, OX3 7LE.
[Ti] Título:Aspirin for acute treatment of episodic tension-type headache in adults.
[So] Source:Cochrane Database Syst Rev;1:CD011888, 2017 01 13.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Tension-type headache (TTH) affects about 1 person in 5 worldwide. It is divided into infrequent episodic TTH (fewer than one headache per month), frequent episodic TTH (two to 14 headache days per month), and chronic TTH (15 headache days per month or more). Aspirin is one of a number of analgesics suggested for acute treatment of episodic TTH. OBJECTIVES: To assess the efficacy and safety of aspirin for acute treatment of episodic tension-type headache (TTH) in adults compared with placebo or any active comparator. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and the Oxford Pain Relief Database from inception to September 2016, and also reference lists of relevant published studies and reviews. We sought unpublished studies by asking personal contacts and searching online clinical trial registers and manufacturers' websites. SELECTION CRITERIA: We included randomised, double-blind, placebo-controlled studies (parallel-group or cross-over) using oral aspirin for symptomatic relief of an acute episode of TTH. Studies had to be prospective, with participants aged 18 years or over, and include at least 10 participants per treatment arm. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for inclusion and extracted data. For various outcomes (predominantly those recommended by the International Headache Society (IHS)), we calculated the risk ratio (RR) and number needed to treat for one additional beneficial outcome (NNT), one additional harmful outcome (NNH), or to prevent one event (NNTp) for oral aspirin compared to placebo or an active intervention.We assessed the evidence using GRADE and created a 'Summary of findings' table. MAIN RESULTS: We included five studies enrolling adults with frequent episodic TTH; 1812 participants took medication, of which 767 were included in comparisons of aspirin 1000 mg with placebo, and 405 in comparisons of aspirin 500 mg or 650 mg with placebo. Not all of these participants provided data for outcomes of interest in this review. Four studies specified using IHS diagnostic criteria; one predated commonly recognised criteria, but described comparable characteristics and excluded migraine. All participants treated headaches of at least moderate pain intensity.None of the included studies were at low risk of bias across all domains considered, although for most studies and domains this was likely to be due to inadequate reporting rather than poor methods. We judged one study to be at high risk of bias due to small size.There were no data for aspirin at any dose for the IHS preferred outcome of being pain free at two hours, or for being pain free at any other time, and only one study provided data equivalent to having no or mild pain at two hours (very low quality evidence). Use of rescue medication was lower with aspirin 1000 mg than with placebo (2 studies, 397 participants); 14% of participants used rescue medication with aspirin 1000 mg compared with 31% with placebo (NNTp 6.0, 95% confidence interval (CI) 4.1 to 12) (low quality evidence). Two studies (397 participants) reported a Patient Global Evaluation at the end of the study; we combined the top two categories for both studies to determine the number of participants who were 'satisfied' with treatment. Aspirin 1000 mg produced more satisfied participants (55%) than did placebo (37%) (NNT 5.7, 95% CI 3.7 to 12) (very low quality evidence).Adverse events were not different between aspirin 1000 mg and placebo (RR 1.1, 95% CI 0.8 to 1.5), or aspirin 500 mg or 650 mg and placebo (RR 1.3, 95% CI 0.8 to 2.0) (low quality evidence). Studies reported no serious adverse events.The quality of the evidence using GRADE comparing aspirin doses between 500 mg and 1000 mg with placebo was low or very low. Evidence was downgraded because of the small number of studies and events, and because the most important measures of efficacy were not reported.There were insufficient data to compare aspirin with any active comparator (paracetamol alone, paracetamol plus codeine, peppermint oil, or metamizole) at any of the doses tested. AUTHORS' CONCLUSIONS: A single dose of aspirin between 500 mg and 1000 mg provided some benefit in terms of less frequent use of rescue medication and more participants satisfied with treatment compared with placebo in adults with frequent episodic TTH who have an acute headache of moderate or severe intensity. There was no difference between a single dose of aspirin and placebo for the number of people experiencing adverse events. The amount and quality of the evidence was very limited and should be interpreted with caution.
[Mh] Termos MeSH primário: Analgésicos/uso terapêutico
Aspirina/uso terapêutico
Cefaleia do Tipo Tensional/tratamento farmacológico
[Mh] Termos MeSH secundário: Acetaminofen/uso terapêutico
Administração Oral
Adulto
Idoso
Analgésicos/administração & dosagem
Analgésicos/efeitos adversos
Aspirina/administração & dosagem
Aspirina/efeitos adversos
Codeína/uso terapêutico
Dipirona/uso terapêutico
Seres Humanos
Meia-Idade
Medição da Dor
Óleos Vegetais/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Analgesics); 0 (Plant Oils); 362O9ITL9D (Acetaminophen); 6429L0L52Y (Dipyrone); AV092KU4JH (peppermint oil); Q830PW7520 (Codeine); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170405
[Lr] Data última revisão:
170405
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170114
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD011888.pub2


  10 / 1325 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27756064
[Au] Autor:Donnerer J; Liebmann I
[Ad] Endereço:Institute of Experimental and Clinical Pharmacology, Medical University Graz, Graz, Austria.
[Ti] Título:Effects of Allyl Isothiocyanate, Acetaminophen, and Dipyrone in the Guinea-Pig Ileum.
[So] Source:Pharmacology;99(1-2):79-83, 2017.
[Is] ISSN:1423-0313
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Allyl isothiocyanate (AITC, mustard oil, 50-200 µmol/l), depending on specific dosages, inhibited the cholinergic twitch response in the longitudinal muscle-myenteric plexus (LMMP) strip of the guinea-pig ileum. AITC also induced short-lasting contractile responses, and decreases of the basal tone of the LMMP strip at low concentrations and increases at high concentrations. Hexamethonium, a blocker of nicotinic ganglionic transmission, was able to prevent the AITC-evoked inhibitory effect, an effect that was also observed with the opioid antagonist naloxone. The P2 purinoceptor antagonist pyridoxalphosphate-6-azophenyl-2'-4'-disulphonic acid and guanethidine had no significant influence on the inhibitory effect of AITC. Since AITC also reduced the electrical stimulation-induced myogenic smooth muscle contractions in the LMMP preparation, its contractile and relaxant actions can be regarded as neurogenic and myogenic in nature. The analgesics, acetaminophen (paracetamol, 100-500 µmol/l) and dipyrone (metamizole, 100-500 µmol/l), reduced both the cholinergic twitch and the myogenic contractions in the LMMP strip to the same extent; therefore, their action in the intestinal smooth muscle can be regarded as myogenic spasmolytic in nature.
[Mh] Termos MeSH primário: Acetaminofen/farmacologia
Dipirona/farmacologia
Íleo/efeitos dos fármacos
Isotiocianatos/farmacologia
Contração Muscular/efeitos dos fármacos
[Mh] Termos MeSH secundário: Analgésicos/farmacologia
Animais
Relação Dose-Resposta a Droga
Cobaias
Íleo/fisiologia
Masculino
Contração Muscular/fisiologia
Antagonistas de Entorpecentes/farmacologia
Técnicas de Cultura de Órgãos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Isothiocyanates); 0 (Narcotic Antagonists); 362O9ITL9D (Acetaminophen); 6429L0L52Y (Dipyrone); BN34FX42G3 (allyl isothiocyanate)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170316
[Lr] Data última revisão:
170316
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161019
[St] Status:MEDLINE
[do] DOI:10.1159/000452164



página 1 de 133 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde